Urine CXCL10 As a Biomarker in Kidney Transplantation

Overview

Journal Curr Opin Organ Transplant

Specialty General Surgery

Date 2024 Jan 18

PMID 38235748

Authors

Patricia Hirt-Minkowski

Stefan Schaub

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Urine CXCL10 is a promising biomarker for posttransplant renal allograft monitoring but is currently not widely used for clinical management.

Recent Findings: Large retrospective studies and data from a prospective randomized trial as well as a prospective cohort study demonstrate that low urine CXCL10 levels are associated with a low risk of rejection and can exclude BK polyomavirus replication with high certainty. Urine CXCL10 can either be used as part of a multiparameter based risk assessment tool, or as an individual biomarker taking relevant confounders into account. A novel Luminex-based CXCL10 assay has been validated in a multicenter study, and proved to be robust, reproducible, and accurate.

Summary: Urine CXCL10 is a well characterized inflammation biomarker, which can be used to guide performance of surveillance biopsies. Wide implementation into clinical practice depends on the availability of inexpensive, thoroughly validated assays with approval from regulatory authorities.

Citing Articles

Biomarkers of Rejection in Kidney Transplantation.

Westphal S, Mannon R Am J Kidney Dis. 2024; 85(3):364-374.

PMID: 39419272 PMC: 11846701. DOI: 10.1053/j.ajkd.2024.07.018.

References

Schaub S, Nickerson P, Rush D, Mayr M, Hess C, Golian M . Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009; 9(6):1347-53. DOI: 10.1111/j.1600-6143.2009.02645.x. View

Tatapudi R, Muthukumar T, Dadhania D, Ding R, Li B, Sharma V . Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004; 65(6):2390-7. DOI: 10.1111/j.1523-1755.2004.00663.x. View

Hu H, Aizenstein B, Puchalski A, Burmania J, Hamawy M, Knechtle S . Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant. 2004; 4(3):432-7. DOI: 10.1111/j.1600-6143.2004.00354.x. View

Sellares J, de Freitas D, Mengel M, Reeve J, Einecke G, Sis B . Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2011; 12(2):388-99. DOI: 10.1111/j.1600-6143.2011.03840.x. View

Rampersad C, Balshaw R, Gibson I, Ho J, Shaw J, Karpinski M . The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am J Transplant. 2021; 22(3):761-771. PMC: 9299170. DOI: 10.1111/ajt.16883. View

Kung V, Sandhu R, Haas M, Huang E . Chronic active T cell-mediated rejection is variably responsive to immunosuppressive therapy. Kidney Int. 2021; 100(2):391-400. DOI: 10.1016/j.kint.2021.03.027. View

Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D . The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. Am J Transplant. 2016; 17(1):28-41. PMC: 5363228. DOI: 10.1111/ajt.14107. View

Hirt-Minkowski P, Handschin J, Stampf S, Hopfer H, Menter T, Senn L . Randomized Trial to Assess the Clinical Utility of Renal Allograft Monitoring by Urine CXCL10 Chemokine. J Am Soc Nephrol. 2023; 34(8):1456-1469. PMC: 10400101. DOI: 10.1681/ASN.0000000000000160. View

Loupy A, Vernerey D, Tinel C, Aubert O, Duong van Huyen J, Rabant M . Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. J Am Soc Nephrol. 2015; 26(7):1721-31. PMC: 4483584. DOI: 10.1681/ASN.2014040399. View

10.

Rabant M, Amrouche L, Lebreton X, Aulagnon F, Benon A, Sauvaget V . Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. J Am Soc Nephrol. 2015; 26(11):2840-51. PMC: 4625672. DOI: 10.1681/ASN.2014080797. View

11.

Jackson J, Kim E, Begley B, Cheeseman J, Harden T, Perez S . Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011; 11(10):2228-34. PMC: 3184377. DOI: 10.1111/j.1600-6143.2011.03680.x. View

12.

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View

13.

Hirt-Minkowski P, Rush D, Gao A, Hopfer H, Wiebe C, Nickerson P . Six-Month Urinary CCL2 and CXCL10 Levels Predict Long-term Renal Allograft Outcome. Transplantation. 2016; 100(9):1988-96. DOI: 10.1097/TP.0000000000001304. View

14.

Ho J, Schaub S, Jackson A, Balshaw R, Carroll R, Cun S . Multicenter Validation of a Urine CXCL10 Assay for Noninvasive Monitoring of Renal Transplants. Transplantation. 2023; 107(7):1630-1641. DOI: 10.1097/TP.0000000000004554. View

15.

Hirt-Minkowski P, Ho J, Gao A, Amico P, Koller M, Hopfer H . Prediction of Long-term Renal Allograft Outcome By Early Urinary CXCL10 Chemokine Levels. Transplant Direct. 2016; 1(8):e31. PMC: 4946476. DOI: 10.1097/TXD.0000000000000537. View

16.

Hirt-Minkowski P, Amico P, Ho J, Gao A, Bestland J, Hopfer H . Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. Am J Transplant. 2012; 12(7):1811-23. DOI: 10.1111/j.1600-6143.2012.03999.x. View

17.

Van Loon E, Tinel C, de Loor H, Bossuyt X, Callemeyn J, Coemans M . Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort Study. Am J Kidney Dis. 2023; 83(4):467-476. DOI: 10.1053/j.ajkd.2023.07.022. View

18.

Haller J, Diebold M, Leuzinger K, Wehmeier C, Handschin J, Amico P . Urine CXCL10 to Assess BK Polyomavirus Replication After Kidney Transplantation. Transplantation. 2023; 107(12):2568-2574. PMC: 10664791. DOI: 10.1097/TP.0000000000004712. View

19.

Pascual J, Berger S, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y . Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol. 2018; 29(7):1979-1991. PMC: 6050928. DOI: 10.1681/ASN.2018010009. View

20.

Ho J, Okoli G, Rabbani R, Lam O, Reddy V, Askin N . Effectiveness of T cell-mediated rejection therapy: A systematic review and meta-analysis. Am J Transplant. 2021; 22(3):772-785. PMC: 9300092. DOI: 10.1111/ajt.16907. View